Headaches

Jonathan M. Borkum July 22, 2019

Background

Calcitonin gene‐related peptide has emerged as a therapeutic target in migraine. Monoclonal antibodies and small molecule receptor antagonists (gepants) directed against CGRP have been approved or are in Phase II or III clinical trials. For monitoring the long‐term safety of these drugs, it is helpful to consider the role of CGRP in brain functioning.… Read More...

Emily F. Law, Scott W. Powers, Heidi Blume, Tonya M. Palermo July 19, 2019

Objective

To present data on psychometric properties of the Psychosocial Assessment Tool 2.0_General (PAT), a brief screener for psychosocial risk in families of youth with medical conditions, in youth with headache.

Background

Emotional and behavioral disturbances, parent distress, and poor family functioning are common among youth with recurrent migraine and tension‐type headache; however, tools to comprehensively screen family and psychosocial risk in youth with headache are not currently available.… Read More...

Paul G. Mathew, Brad C. Klein July 19, 2019

Abstract

Premise

The science of migraine pathophysiology has advanced significantly since the 1930’s. Imaging techniques, neurochemical analysis, clinical trials, and the clinical experience of providers treating migraine patients have not only sharpened our understanding of the disease, but have also led to the development of novel neural‐based targets.… Read More...

Randolph W. Evans July 17, 2019

Two cases are reported of migraineurs who reported Raynaud’s phenomenon (RP) exacerbated while taking monoclonal antibodies to the calcitonin gene‐related peptide (CGRP) ligand (fremanezumab and galcanezumab) and 1 case of new onset RP while taking the CGRP receptor antagonist (erenumab). The prevalence of primary and secondary RP, causes of secondary RP, co‐morbidity with migraine, and medications which might induce or exacerbate RP are reviewed.… Read More...

Ioanna Spanou, Anastasia Bougea, George Liakakis, Konstantina Rizonaki, Evangelos Anagnostou, Leonidas Duntas, Evangelia Kararizou July 17, 2019

Background

Migraine, tension‐type headache, and hypothyroidism constitute very common medical conditions. Headache is one of the most common symptoms of hypothyroidism, occurring in approximately one‐third of the patients. To date, data about the relationship between migraine and tension‐type headache and thyroid dysfunction, and in particular hypothyroidism have been contradictory, while the underlying pathophysiological basis explaining this association is still unclear.… Read More...

Caroline M Kopruszinski July 17, 2019

Cephalalgia, Ahead of Print.
AimEvaluation of cannabinoid receptor agonists in a preclinical model of medication overuse headache.MethodsFemale Sprague Dawley rats received graded intraperitoneal doses of WIN55,212-2 or Δ-9-tetrahydrocannabinol (Δ-9-THC). Antinociception (tail-flick test), catalepsy and hypomotility (open field test) and impairment of motor function (rotarod test) were assessed to establish effective dosing.… Read More...

Ai Seon Kuan July 16, 2019

Cephalalgia, Ahead of Print.
BackgroundMigraine is associated with syncope. We investigated risk factors for syncope and burden of syncope in migraine patients.MethodsParticipants were recruited from a headache clinic. All participants provided information on lifestyle, co-morbidity, syncope, headache and suicide, and completed the MIDAS and HADS questionnaires.… Read More...

Andoird App
Loading...